CPI-637

CAS No. 1884712-47-3

CPI-637 ( CPI637;CPI 637 )

Catalog No. M12946 CAS No. 1884712-47-3

A potent and selective, cell-active CBP/EP300 bromodomain inhibitor with CBP BRET EC50 of 0.03 uM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 42 In Stock
5MG 64 In Stock
10MG 92 In Stock
25MG 201 In Stock
50MG 357 In Stock
100MG 537 In Stock
500MG 1134 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CPI-637
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent and selective, cell-active CBP/EP300 bromodomain inhibitor with CBP BRET EC50 of 0.03 uM.
  • Description
    A potent and selective, cell-active CBP/EP300 bromodomain inhibitor with CBP BRET EC50 of 0.03 uM; displays >700-fold selectivity over the BET bromodomains (BRD4 IC50=11.0 uM), also highly selective against other bromodomains; inhibits the expression of MYC with an EC50 of 0.60 uM in a cellular assay.
  • Synonyms
    CPI637;CPI 637
  • Pathway
    Chromatin/Epigenetic
  • Target
    Bromodomain
  • Recptor
    BRD4;CBP;EP300
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    1884712-47-3
  • Formula Weight
    386.45
  • Molecular Formula
    C22H22N6O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO
  • SMILES
    CN(N=C1C2=CN(C)N=C2)C3=C1C=C(C4=CC=CC(N5)=C4N[C@H](C)CC5=O)C=C3
  • Chemical Name
    2H-1,5-Benzodiazepin-2-one, 1,3,4,5-tetrahydro-4-methyl-6-[1-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl]-, (4R)-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Taylor AM, et al. ACS Med Chem Lett. 2016 Mar 15;7(5):531-6.
molnova catalog
related products
  • FL-411

    FL-411 is a novel small-molecule inhibitor of BRD4.

  • RX-37

    A potent and specific BET bromodomain inhibitor with Ki of 3.2-24.7 nM.

  • SJ830599

    SJ830599 is a modest selective BRD2-BD2 inhibitor with IC50 of 0.61 uM, 3.3-fold selectivity over BRD2-BD1.